Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential

Escape from Human Monoclonal Antibody Neutralization Affects In Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome Coronavirus

(2010) Barry Rockx et al.   JOURNAL OF INFECTIOUS DISEASES

Development trends for human monoclonal antibody therapeutics

(2010) Aaron L. Nelson et al.   NATURE REVIEWS DRUG DISCOVERY

Immunogenicity difference between the SARS coronavirus and the bat SARS-like coronavirus spike (S) proteins

(2009) Peng Zhou et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phylogenetic perspectives on the epidemiology and origins of SARS and SARS-like coronaviruses

(2009) Chi Wai Yip et al.   INFECTION GENETICS AND EVOLUTION

Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission

(2009) R. L. Graham et al.   JOURNAL OF VIROLOGY

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

(2009) Lanying Du et al.   NATURE REVIEWS MICROBIOLOGY

Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms

(2009) Melissa M. Coughlin et al.   VIROLOGY

Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge

(2008) B. Rockx et al.   JOURNAL OF VIROLOGY

Cathepsin L Functionally Cleaves the Severe Acute Respiratory Syndrome Coronavirus Class I Fusion Protein Upstream of Rather than Adjacent to the Fusion Peptide

(2008) B. J. Bosch et al.   JOURNAL OF VIROLOGY

Broadening of Neutralization Activity to Directly Block a Dominant Antibody-Driven SARS-Coronavirus Evolution Pathway

(2008) Jianhua Sui et al.   PLoS Pathogens